×

Sonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call

PETALUMA, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that financial results for its fiscal second quarter 2018, ended September 30, 2017, will be released after the U.S. markets close on November 9, 2017. The earnings release will be followed by a conference call at 1:30 p.m. PST on November 9, 2017, to discuss fiscal second quarter results.

Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those interested in listening to the conference call live via the internet may do so at http://ir.sonomapharma.com/events.cfm.

A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 85466211. A webcast replay will be available on the site at http://ir.sonomapharma.com/events.cfm for one year following the call.

About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.

Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@sonomapharma.com

Source:Sonoma Pharmaceuticals, Inc.